Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT02924883
Registration number
NCT02924883
Ethics application status
Date submitted
21/09/2016
Date registered
5/10/2016
Date last updated
17/02/2021
Titles & IDs
Public title
A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer (BC) Who Received Prior Trastuzumab and Taxane Based Therapy
Query!
Scientific title
A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase II Study of the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Trastuzumab and Taxane Based Therapy
Query!
Secondary ID [1]
0
0
2015-004189-27
Query!
Secondary ID [2]
0
0
WO30085
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
KATE2
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Metastatic Breast Cancer
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Breast
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Atezolizumab
Treatment: Drugs - Trastuzumab emtansine
Other interventions - Placebo
Experimental: Trastuzumab Emtansine + Atezolizumab - Atezolizumab 1200 milligrams (mg) intravenous (IV) infusion or matching Placebo followed by trastuzumab emtansine 3.6 milligrams per kilogram (mg/kg) IV infusion on Day 1 Cycle 1 and thereafter on Day 1 of each 21-day cycle until disease progression, unmanageable toxicity, or study termination by the Sponsor (approximately 29 months)
Active comparator: Trastuzumab Emtansine + Placebo - Placebo matched to atezolizumab followed by trastuzumab emtansine 3.6 mg/kg IV infusion on Day 1 Cycle 1 and thereafter on Day 1 of each 21-day cycle until disease progression, unmanageable toxicity, or study termination by the sponsor (approximately 29 months)
Treatment: Drugs: Atezolizumab
Atezolizumab 1200 mg IV infusion
Treatment: Drugs: Trastuzumab emtansine
Trastuzumab emtansine 3.6 mg/kg IV infusion
Other interventions: Placebo
Placebo matched to atezolizumab
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Intervention code [2]
0
0
Other interventions
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Progression-Free Survival (PFS) as Determined by Investigator's Tumor Assessment Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v1.1)
Query!
Assessment method [1]
0
0
PFS was defined as the time from randomization to the first occurrence of disease progression or death from any cause, whichever occurred first, on the basis of investigator assessments. Progression was defined as at least a 20% increase in the sum of diameters of target lesions with an absolute increase of at least 5 millimeter (mm) or the appearance of one or more new lesions.
Query!
Timepoint [1]
0
0
Baseline up to approximately 15 months
Query!
Primary outcome [2]
0
0
Percentage of Participants With Adverse Events
Query!
Assessment method [2]
0
0
An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.
Query!
Timepoint [2]
0
0
Baseline up to study completion, approximately 40 months
Query!
Secondary outcome [1]
0
0
Overall Survival (OS)
Query!
Assessment method [1]
0
0
OS was defined as the time from randomization to death from any cause.
Query!
Timepoint [1]
0
0
Baseline up to study completion or death, whichever occurs first, approximately 40 months
Query!
Secondary outcome [2]
0
0
Percentage of Participants With Objective Response (OR) as Determined by Investigator's Tumor Assessment Using RECIST v1.1
Query!
Assessment method [2]
0
0
An OR was defined as a complete or partial response determined on 2 consecutive occasions = 4 weeks apart using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Complete response was defined as the disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) must be \< 10 mm on the short axis. Partial response was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum. Participants who had no post-baseline tumor assessment were counted as non-responders.
Query!
Timepoint [2]
0
0
Baseline up to approximately 15 months
Query!
Secondary outcome [3]
0
0
Duration of OR as Determined by Investigator's Tumor Assessment Using RECIST v1.1
Query!
Assessment method [3]
0
0
Duration of OR was defined as the time from the first tumor assessment that was judged to indicate that the patient had an objective response to the time of first documented disease progression using RECIST v1.1 per investigator assessment or death from any cause, whichever occurred first.
Query!
Timepoint [3]
0
0
Baseline up to approximately 15 months
Query!
Secondary outcome [4]
0
0
Maximum Serum Concentration (Cmax) of Trastuzumab Emtansine
Query!
Assessment method [4]
0
0
Average post infusion Trastuzumab Emtansine concentration
Query!
Timepoint [4]
0
0
Pre-infusion (0 hour [h]), 30 minutes (min) after end of infusion (EOI) (over 90 min) on Day 1 Cycles 1 and 4; pre-infusion (0 h) on Day 1 Cycle 2 (each cycle = 21 days); at any time during study treatment/early discontinuation visit (approx. 40 months)
Query!
Secondary outcome [5]
0
0
Cmax of Deacetyl Mercapto 1-Oxopropyl Maytansine (DM1)
Query!
Assessment method [5]
0
0
Average post infusion Deacetyl Mercapto 1-Oxopropyl Maytansine concentration of trastuzumab emtansine infusion
Query!
Timepoint [5]
0
0
Pre-infusion (0 h) on Day 1 Cycle 1 and 30 min after EOI (over 90 min) on Day 1 Cycles 1 and 4 (each cycle = 21 days)
Query!
Secondary outcome [6]
0
0
Cmax of Total Trastuzumab
Query!
Assessment method [6]
0
0
Query!
Timepoint [6]
0
0
Pre-infusion (0 h), 30 min after EOI (over 90 min) on Day 1 Cycles 1 and 4; pre-infusion (0 h) on Day 1 Cycle 2 (each cycle = 21 days)
Query!
Secondary outcome [7]
0
0
Cmax of Atezolizumab
Query!
Assessment method [7]
0
0
Average post infusion atezolizumab concentration
Query!
Timepoint [7]
0
0
Pre-infusion (0 h), 30 min after EOI (over 60 min) on Day 1 Cycles 1 and 4; pre-infusion (0 h) on Day 1 Cycles 2, 3, 8, and every 8 cycles thereafter (each cycle=21 days) up to 120 days after treatment completion/early discontinuation (approx. 40 months)
Query!
Secondary outcome [8]
0
0
Percentage of Participants With Anti-therapeutic Antibodies (ATAs) to Atezolizumab
Query!
Assessment method [8]
0
0
ATAs are antibodies that inactivate the therapeutic effects of Atezolizumab. Patients are considered to be ATA positive if they are ATA negative at baseline but develop an ATA response following study drug administration (treatment-induced ATA response), or if they are ATA positive at baseline and the titer of one or more post-baseline samples is at least 4-fold greater (i.e., = 0.60 titer units) than the titer of the baseline sample (treatment-enhanced ATA response).
Query!
Timepoint [8]
0
0
Pre-infusion (0 h) on Day 1 Cycles 1, 2, 3, 4, 8, and every 8 cycles thereafter (each cycle = 21 days) up to 120 days after treatment completion or early discontinuation (approximately 40 months)
Query!
Secondary outcome [9]
0
0
Percentage of Participants With ATAs to Trastuzumab Emtansine
Query!
Assessment method [9]
0
0
ATAs are antibodies that inactivate the therapeutic effects of Trastuzumab Emtansine. Patients are considered to be ATA positive if they are ATA negative at baseline but develop an ATA response following study drug administration (treatment-induced ATA response), or if they are ATA positive at baseline and the titer of one or more post-baseline samples is at least 4-fold greater (i.e., = 0.60 titer units) than the titer of the baseline sample (treatment-enhanced ATA response).
Query!
Timepoint [9]
0
0
Pre-infusion (0 h) on Day 1 Cycles 1 and 4 (each cycle = 21 days); and at any time during study treatment/early discontinuation visit (approximately 40 months)
Query!
Eligibility
Key inclusion criteria
* Archival tumor samples must be obtained from primary and/or metastatic sites
* Able to submit tumor tissue that is evaluable for programmed death- ligand 1 (PD-L1) expression
* HER-2 positive BC as defined by an immunohistochemistry score of 3 or gene amplified by in-situ hybridization as defined by a ratio of greater than or equal to (>=) 2.0 for the number of HER2 gene copies to the number of chromosome 17 copies
* Histologically or cytologically confirmed invasive BC: incurable, unresectable, locally advanced BC previously treated with multimodality therapy or metastatic BC
* Prior treatment for BC in the: adjuvant; unresectable locally advanced; or metastatic settings; which must include both, a taxane and trastuzumab (alone or in combination with another agent)
* Progression must have occurred during or after most recent treatment for locally advanced/metastatic BC or within 6 months after completing adjuvant therapy
* Participants must have measurable disease that is evaluable as per RECIST v1.1
* Eastern Cooperative Oncology Group Performance Status of 0 or 1
* Negative serum pregnancy test within 7 days of enrollment for pre-menopausal women and for women less than 12 months after the onset of menopause
* Use of highly effective method of contraception as defined by the protocol
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Prior treatment with trastuzumab emtansine, cluster of differentiation 137 agonists, anti-programmed death-1, or anti-PD-L1 therapeutic antibody or pathway-targeting agents
* Receipt of any anti-cancer drug/biologic or investigational treatment within 21 days prior to Cycle 1 Day 1 except hormone therapy, which can be given up to 7 days prior to Cycle 1 Day 1; recovery of treatment related toxicity consistent with other eligibility criteria
* Radiation therapy within 2 weeks prior to Cycle 1, Day 1
* History of exposure to the cumulative doses of anthracyclines
* History of other malignancy within the previous 5 years, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, Stage I uterine cancer, or participants who have undergone potentially curative therapy with no evidence of disease and are deemed by the treating physician to be at low risk for recurrence
* Cardiopulmonary dysfunction, symptomatic pleural effusion, pericardial effusion, or ascites
* Participants with severe infection within 4 weeks prior to randomization, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumonia
* Current severe, uncontrolled systemic disease
* Major surgical procedure or significant traumatic injury within 28 days prior to randomization or anticipation of the need for major surgery during the course of study treatment
* Clinically significant history of liver disease, including cirrhosis, current alcohol abuse, autoimmune hepatic disorders, sclerosis cholangitis or active infection with human immunodeficiency virus, hepatitis B virus, or hepatitis C virus
* Need for current chronic corticosteroid therapy (>=10 mg of prednisone per day or an equivalent dose of other anti-inflammatory corticosteroids)
* Spinal cord compression not definitively treated with surgery and/or radiation, or previously diagnosed and treated spinal cord compression without evidence that disease has been clinically stable for greater than (>) 2 weeks prior to randomization
* Participants with known central nervous system disease
* Leptomeningeal disease
* History of autoimmune disease
* Prior allogeneic stem cell or solid organ transplantation
* Active tuberculosis
* Receipt of a live, attenuated vaccine within 4 weeks prior to randomization or anticipation that such a live, attenuated vaccine will be required during the study
* Treatment with systemic immunostimulatory agents within 4 weeks or five half-lives of the drug (whichever is shorter) prior to randomization
* Treatment with systemic corticosteroids or other systemic immunosuppressive medications within 2 weeks prior to randomization, or anticipated requirement for systemic immunosuppressive medications during the trial
* Participants who are breastfeeding, or intending to become pregnant during the study
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
26/09/2016
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
6/02/2020
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
202
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC,WA
Query!
Recruitment hospital [1]
0
0
St George Hospital; Cancer Care Centre - Kogarah
Query!
Recruitment hospital [2]
0
0
Calvary Mater Newcastle - Waratah
Query!
Recruitment hospital [3]
0
0
Princess Alexandra Hospital Woolloongabba; Clinical Hematology and Medical Oncology - Woolloongabba
Query!
Recruitment hospital [4]
0
0
Peter MacCallum Cancer Center - East Melbourne
Query!
Recruitment hospital [5]
0
0
Peninsula and South Eastern Haematology and Oncology Group - Frankston
Query!
Recruitment hospital [6]
0
0
Sunshine Hospital - St Albans
Query!
Recruitment hospital [7]
0
0
St John of God Hospital; Bendat Cancer Centre - Subiaco
Query!
Recruitment postcode(s) [1]
0
0
2217 - Kogarah
Query!
Recruitment postcode(s) [2]
0
0
2298 - Waratah
Query!
Recruitment postcode(s) [3]
0
0
4102 - Woolloongabba
Query!
Recruitment postcode(s) [4]
0
0
3002 - East Melbourne
Query!
Recruitment postcode(s) [5]
0
0
3199 - Frankston
Query!
Recruitment postcode(s) [6]
0
0
3021 - St Albans
Query!
Recruitment postcode(s) [7]
0
0
6008 - Subiaco
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Colorado
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
District of Columbia
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Florida
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Georgia
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Maryland
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
New Mexico
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
New York
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Ohio
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Pennsylvania
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Tennessee
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Washington
Query!
Country [13]
0
0
Canada
Query!
State/province [13]
0
0
Ontario
Query!
Country [14]
0
0
Canada
Query!
State/province [14]
0
0
Quebec
Query!
Country [15]
0
0
Germany
Query!
State/province [15]
0
0
Berlin
Query!
Country [16]
0
0
Germany
Query!
State/province [16]
0
0
Essen
Query!
Country [17]
0
0
Germany
Query!
State/province [17]
0
0
Freiburg
Query!
Country [18]
0
0
Germany
Query!
State/province [18]
0
0
Heidelberg
Query!
Country [19]
0
0
Germany
Query!
State/province [19]
0
0
Koblenz
Query!
Country [20]
0
0
Italy
Query!
State/province [20]
0
0
Campania
Query!
Country [21]
0
0
Italy
Query!
State/province [21]
0
0
Emilia-Romagna
Query!
Country [22]
0
0
Italy
Query!
State/province [22]
0
0
Friuli-Venezia Giulia
Query!
Country [23]
0
0
Italy
Query!
State/province [23]
0
0
Sicilia
Query!
Country [24]
0
0
Italy
Query!
State/province [24]
0
0
Toscana
Query!
Country [25]
0
0
Korea, Republic of
Query!
State/province [25]
0
0
Goyang-si
Query!
Country [26]
0
0
Korea, Republic of
Query!
State/province [26]
0
0
Seoul
Query!
Country [27]
0
0
Spain
Query!
State/province [27]
0
0
Cordoba
Query!
Country [28]
0
0
Spain
Query!
State/province [28]
0
0
Barcelona
Query!
Country [29]
0
0
Spain
Query!
State/province [29]
0
0
La Coruña
Query!
Country [30]
0
0
Spain
Query!
State/province [30]
0
0
Madrid
Query!
Country [31]
0
0
Spain
Query!
State/province [31]
0
0
Valencia
Query!
Country [32]
0
0
Taiwan
Query!
State/province [32]
0
0
Changhua
Query!
Country [33]
0
0
Taiwan
Query!
State/province [33]
0
0
Kaohsiung
Query!
Country [34]
0
0
Taiwan
Query!
State/province [34]
0
0
Taichung
Query!
Country [35]
0
0
Taiwan
Query!
State/province [35]
0
0
Tainan
Query!
Country [36]
0
0
Taiwan
Query!
State/province [36]
0
0
Taipei City
Query!
Country [37]
0
0
Taiwan
Query!
State/province [37]
0
0
Taipei
Query!
Country [38]
0
0
Taiwan
Query!
State/province [38]
0
0
Taoyuan
Query!
Country [39]
0
0
United Kingdom
Query!
State/province [39]
0
0
Bath
Query!
Country [40]
0
0
United Kingdom
Query!
State/province [40]
0
0
Glasgow
Query!
Country [41]
0
0
United Kingdom
Query!
State/province [41]
0
0
London
Query!
Country [42]
0
0
United Kingdom
Query!
State/province [42]
0
0
Manchester
Query!
Country [43]
0
0
United Kingdom
Query!
State/province [43]
0
0
Nottingham
Query!
Country [44]
0
0
United Kingdom
Query!
State/province [44]
0
0
Sheffield
Query!
Country [45]
0
0
United Kingdom
Query!
State/province [45]
0
0
Sutton
Query!
Country [46]
0
0
United Kingdom
Query!
State/province [46]
0
0
Swansea
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Hoffmann-La Roche
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This Phase II, double-blind, randomized, placebo-controlled multicenter study will investigate the efficacy and safety of trastuzumab emtansine in combination with atezolizumab or atezolizumab-placebo in participants with HER2-positive locally advanced or metastatic BC who have received prior trastuzumab and taxane based therapy, either alone or in combination, and/or who have progressed within 6 months after completing adjuvant therapy.
Query!
Trial website
https://clinicaltrials.gov/study/NCT02924883
Query!
Trial related presentations / publications
Emens LA, Esteva FJ, Beresford M, Saura C, De Laurentiis M, Kim SB, Im SA, Wang Y, Salgado R, Mani A, Shah J, Lambertini C, Liu H, de Haas SL, Patre M, Loi S. Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial. Lancet Oncol. 2020 Oct;21(10):1283-1295. doi: 10.1016/S1470-2045(20)30465-4.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Clinical Trials
Query!
Address
0
0
Hoffmann-La Roche
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Type
Other Details
Attachment
Study protocol
https://cdn.clinicaltrials.gov/large-docs/83/NCT02924883/Prot_000.pdf
Statistical analysis plan
https://cdn.clinicaltrials.gov/large-docs/83/NCT02924883/SAP_001.pdf
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT02924883
Download to PDF